Gilead tender offer at C$2.95/share cash (~$510M) for YM BioSciences. Acquired CYT387 (momelotinib), JAK1/JAK2 inhibitor for myelofibrosis with positive Phase 1/2 data in 166 patients. Phase 3 planned for H2 2013.
Did it work? Outcome assessment
Strategic verdict
Failed to Achieve
Financial impact
Impaired/Written Down
Pipeline outcome
Assets Stalled
Assessment window: 5yr post-close.
Key facts
AnnouncedDec 11, 2012
ClosedFeb 08, 2013
Deal value$510M
Deal typeAcquisition/Merger
Therapeutic areaMyelofibrosis and other myeloproliferative neoplasms
IndicationsMyelofibrosis and other myeloproliferative neoplasms